AZD0914
AstraZeneca opens new global strategic R&D centre in US
The new centre will be home to nearly 2,000 world-class researchers and scientists
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer
The results from a global phase 3 trial show the longest survival data ever reported in this setting
FDA approves Priovant’s Lisraya for dermatomyositis
This is the first oral drug treatment for this rare disease in adults
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe